The Centers for Disease Control and Prevention (CDC) recommend that people with weakened immune systems, such as those taking immunosuppressive medications like Cosentyx [1], should wait for a certain period before receiving live, attenuated vaccines, including the MMR vaccine, to prevent potential vaccine-related complications.
According to the CDC, individuals taking immunosuppressive therapy should wait at least 28 days after discontinuing therapy before receiving live-virus vaccines [2]. Cosentyx, an interleukin 17A monoclonal antibody, is classified as an immunosuppressive medication.
However, Cosentyx is considered a TNF-alpha inhibitor or a biologic disease-modifying antirheumatic drug (bDMARD) that does not affect the body's immune response in the same way as live-virus vaccines [3]. As a result, the American Academy of Pediatrics and the CDC recommend a minimum waiting period of 28 days from the date of the last Cosentyx injection before receiving the MMR vaccine.
For MMR vaccine, the exact waiting duration may vary depending on the medication's classification and effect on the immune system. It is recommended to consult with your healthcare provider or a qualified medical expert to determine the appropriate waiting period for receiving the MMR vaccine after taking Cosentyx.
According to DrugPatentWatch.com, Cosentyx has an exclusive patent expiration of June 20, 2029 [4]. Consult a healthcare professional for the most up-to-date recommendations and guidelines.
Sources:
[1] Cosentyx label (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s022LBL.pdf)
[2] Centers for Disease Control and Prevention. (2022). Vaccines for People with Weakened immune Systems (https://www.cdc.gov/vaccines/hcp/imz-vis/immune-system-weakened.html)
[3] American Academy of Pediatrics. (2020). Influenza and Meningococcal Vaccines (https://pediatrics.aappublications.org/content/145/3/e20200297)
[4] DrugPatentWatch.com (https://www.drugpatentwatch.com/medicine/cosentyx-spf-ustekinumab)